Kaneq Bioscience Ltd., a Montreal, Canada-based biotechnology company focused on developing treatments for type 2 diabetes, received an investment of undisclosed amount from TVM Life Science Ventures VII.
A spin out of Kaneq Pharma Inc., a biotechnology company developing early stage compounds for metabolic diseases and cancer, Kaneq Bioscience was specifically created to develop a protein tyrosine phosphatase1B (PTP-1B) inhibitor for treating type 2 diabetes mellitus.
Dr. Daniel Bouthillier, CEO of Kaneq Pharma Inc., has joined Kaneq Bioscience as Executive Chairman.
Dr. Cynthia Lavoie, General Partner of TVM Capital Life Science, is a Board Member of the company.
FinSMEs
22/01/2013